Malignant insulinoma: effects of a somatostatin analog (compound 201-995) on serum glucose, growth, and gastro-entero-pancreatic hormones.
Osei
K
K
O'Dorisio
T M
TM
D007516:Adenoma, Islet Cell / Q000188:drug therapy*; D000368:Aged; D001786:Blood Glucose / Q000378:metabolism; D002096:C-Peptide / Q000097:blood; D005260:Female; D013006:Growth Hormone / Q000097:blood; D006207:Half-Life; D006728:Hormones / Q000097:blood*; D006801:Humans; D007328:Insulin / Q000097:blood; D007340:Insulinoma / Q000097:blood / Q000188:drug therapy*; D015282:Octreotide; D010190:Pancreatic Neoplasms / Q000097:blood / Q000188:drug therapy*; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use
D001786:Blood Glucose; D002096:C-Peptide; D006728:Hormones; D007328:Insulin; D013004:Somatostatin; D013006:Growth Hormone; D015282:Octreotide